Cambridge, MA, United States of America

Pia Kasperkovitz

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2019-2023

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Pia Kasperkovitz: Innovator in Nucleic Acid Delivery

Introduction

Pia Kasperkovitz is a notable inventor based in Cambridge, MA, who has made significant contributions to the field of nucleic acid delivery. With a focus on improving methods for administering lipid-formulated nucleic acid molecules, her work has the potential to enhance therapeutic outcomes for various medical conditions.

Latest Patents

Kasperkovitz holds two patents that showcase her innovative approaches. The first patent details dosages and methods for delivering lipid-formulated nucleic acid molecules, specifically aimed at reducing hypersensitivity responses to RNA molecules. The second patent reiterates similar methodologies, emphasizing the importance of effective dosing strategies in clinical applications.

Career Highlights

Pia Kasperkovitz is currently employed at Alnylam Pharmaceuticals, Inc., where she continues to advance her research in the field of nucleic acid therapeutics. Her work at Alnylam has positioned her as a key player in the development of novel treatments that leverage lipid formulations for improved delivery of genetic materials.

Collaborations

Kasperkovitz collaborates with various professionals in her field, including her coworker Jared Gollob. These collaborations enhance the research environment and foster innovation within the company.

Conclusion

Pia Kasperkovitz is a pioneering inventor whose work in nucleic acid delivery is paving the way for new therapeutic strategies. Her patents and contributions to Alnylam Pharmaceuticals highlight her commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…